Institute for Health Research, University of Bedfordshire, Luton, Bedfordshire, UK.
School of Health and Society, University of Salford, Manchester, UK.
BMC Nephrol. 2019 Jun 26;20(1):234. doi: 10.1186/s12882-019-1410-2.
The international evidence about outcomes of End Stage Kidney Disease (ESKD) for ethnic minorities was reviewed to identify gaps and make recommendations for researchers and policy makers.
Nine databases were searched systematically with 112 studies from 14 different countries included and analysed to produce a thematic map of the literature.
Reviews (n = 26) highlighted different mortality rates and specific causes between ethnic groups and by stage of kidney disease associated with individual, genetic, social and environmental factors. Primary studies focussing on uptake of treatment modalities (n = 19) found ethnic differences in access. Research evaluating intermediate outcomes and quality of care in different treatment phases (n = 35) e.g. dialysis adequacy, transplant evaluation and immunosuppression showed ethnic minorities were disadvantaged. This is despite a survival paradox for some ethnic minorities on dialysis seen in studies of longer term outcomes (n = 29) e.g. in survival time post-transplant and mortality. There were few studies which focussed on end of life care (n = 3) and ethnicity. Gaps identified were: limited evidence from all stages of the ESKD pathway, particularly end of life care; a lack of system oriented studies with a reliance on national routine datasets which are limited in scope; a dearth of qualitative studies; and a lack studies from many countries with limited cross country comparison and learning.
Differences between ethnic groups occur at various points and in a variety of outcomes throughout the kidney care system. The combination of individual factors and system related variables affect ethnic groups differently indicating a need for culturally intelligent policy informed by research to prevent disadvantage.
对少数民族终末期肾病(ESKD)结局的国际证据进行了综述,以确定差距,并为研究人员和政策制定者提出建议。
系统地搜索了 9 个数据库,纳入了来自 14 个不同国家的 112 项研究进行分析,生成了文献的主题地图。
综述(n=26)强调了不同种族群体之间以及与肾病阶段相关的不同死亡率和特定病因,这与个体、遗传、社会和环境因素有关。关注治疗方式采用情况的原始研究(n=19)发现了不同种族之间在获得治疗方面的差异。评估不同治疗阶段的中间结局和护理质量的研究(n=35),例如透析充分性、移植评估和免疫抑制,表明少数民族处于不利地位。尽管在一些研究中观察到某些少数民族在透析治疗中的生存悖论,例如在移植后的生存时间和死亡率方面(n=29)。但很少有研究关注终末期护理(n=3)和种族问题。确定的差距包括:ESKD 各个阶段的证据有限,特别是终末期护理;缺乏系统导向的研究,对国家常规数据集的依赖有限,范围有限;缺乏定性研究;并且来自许多国家的研究很少,跨境比较和学习有限。
在整个肾脏护理系统中,不同种族群体在不同时间点和各种结局中存在差异。个体因素和系统相关变量的组合对不同种族群体产生不同的影响,这表明需要根据研究制定文化智能政策,以防止劣势。